Clinical and economic impact of aliskiren in uncontrolled hypertensive patients
BACKGROUND: the majority of hypertensive patients do not achieve adequate blood pressure (BP) control and thus remain at risk of cardio-cerebrovascular events. Aliskiren, a novel antihypertensive drug acting as direct renin inhibitor, was authorized in Italy for the treatment of hypertension in pati...
Main Authors: | Ezio Degli Esposti, Radovan Tomic |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2012-03-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/199 |
Similar Items
-
Renoprotective effect of aliskiren monotherapy and aliskiren−pentoxifylline combination in hypertensive-diabetic type 2 patients with diabetic nephropathy
by: Amin T. Hamed, et al.
Published: (2013-12-01) -
Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews
by: Qiyuan Zhao, et al.
Published: (2020-04-01) -
Budget impact analysis of use of aliskiren in hypertension on the Italian Health Care System
by: Orietta Zaniolo, et al.
Published: (2009-03-01) -
Aliskiren, Obat Antihipertensi Baru dengan Mekanisme Penghambat Renin
by: Diana Holidah
Published: (2011-12-01) -
ALISKIREN (RENIN INHIBITOR) AS THE RECENT ANTIHYPERTENSIVE MODALITY
by: Luh Gde Primahatini Suaka Putri
Published: (2013-12-01)